2-propanol has been researched along with carboplatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Leahey, A; Manquez, ME; Meadows, AT; Shields, CL; Shields, JA; Sun, H | 1 |
| Patel, J; Shields, CL; Turaka, K | 1 |
| Huang, Z; Zhang, Y | 1 |
3 other study(ies) available for 2-propanol and carboplatin
| Article | Year |
|---|---|
Resolution of iris neovascularization following chemoreduction of advanced retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Fluorescein Angiography; Glaucoma, Neovascular; Humans; Infant; Iris; Neovascularization, Pathologic; Retinal Neoplasms; Retinoblastoma; Vincristine | 2006 |
Resolution of iris neovascularization following chemoreduction of retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide; Female; Humans; Iris; Neovascularization, Pathologic; Retinal Neoplasms; Retinoblastoma; Treatment Outcome; Ultrasonography; Vincristine; Visual Acuity | 2010 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |